Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 477

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 477
---
11,343 |  11,178 |     12,793 |
| Share of profit/(loss) from investments accounted for using the equity method(b) |   -136 |    -101 |        -76 |
| Net income attributable to non-controlling interests(c)                          |     14 |      18 |         16 |
| Amortization and impairment of intangible assets(d)                              | -1,997 |  -2,807 |     -1,375 |
| Fair value remeasurement of contingent consideration                             |    -96 |     -93 |         27 |
| Expenses arising from the impact of acquisitions on inventories(e)               |    -10 |      -9 |         -3 |
| Restructuring costs and similar items(f)                                         | -1,396 |  -1,030 |     -1,077 |
| Other gains and losses, and litigation(g)                                        |   -470 |    -196 |       -143 |
| Operating income                                                                 |  7,252 |   6,960 |     10,162 |
| Financial expenses                                                               | -1,073 |  -1,293 |       -430 |
| Financial income                                                                 |    519 |     584 |        205 |
| Income before tax and investments accounted for using the equity method          |  6,698 |   6,251 |      9,937 |

( a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued

operation.

(b) Joint ventures and associates with which Sanofi has entered into a strategic alliance.

(c) Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests.

(d) For 2024, this line includes a net impairment charge of € 248 million mainly due to a recognition of impairment losses of € 640 million against on various

research and development projects – including a € 239million loss resulting from the decision taken in February 2025 to discontinue a phase 3 clinical

study investigating of a vaccine candidate to prevent invasive E.coli disease - partially offset by impairment losses reversals , recognized in connection

with the disposals of the ProXTen platform and Enjaymo, for € 225 million and € 167 million respectively. For 2023, this amount mainly comprises an

impairment loss of € 833